Table 2C. Results of molecular and immunological analyses of GBS and control patients in French Polynesia 2013-2014.
ZIKV and DENV serological patterns associated with GBS
| GBSa (n=42) | CTR1 (n=98) | OR [95% CI] | ORa [95% CI] | CTR2 (n=70) | OR [95% CI] | ORa [95% CI] | |
|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | |||||
| ZIKV IgM and/or IgG positivity | 41 (97.6) | 35 (35.7) | 59.7 [10.4 - +∞] | ||||
| Positive ZIKV seroneutralization | 42 (100.0) | 54 (55.7) | 34.1 [5.8 - +∞] | ||||
| DENV IgG positivity | 40 (95.2) | 87 (88.8) | 2.0 [0.4 - 19.9] | 1.0 [0.2 - 11.5] | 58 (82.9) | 6.0 [0.8 - 269.5] | 4.0 [0.5-184.7] |
a
Tested samples for GBS patients are late samples (±3 months after admission)
b
Adjusted for ZIKV IgG positivity